Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3415406 | 0.92 | CHRNA7 (0.42) | CHRNA7 | |
| SCHEMBL3408479 | 0.82 | CHRNA7 (0.41) | CHRNA7 | |
| SCHEMBL1114394 | 0.80 | MAPK1 (0.41) | CHRNA7 | |
| Hydrochloric Acid SCHEMBL7809740 | 0.78 | CHRNA7 (0.40) | CHRNA7 | |
| SCHEMBL3408506 | 0.73 | TSHR (0.31) | — | |
| SCHEMBL2957850 | 0.72 | MAPK1 (0.54) | CHRNA7 | |
| SCHEMBL14094910 | 0.71 | — | — | |
| SCHEMBL1922253 | 0.71 | MAPK1 (0.52) | — | |
| SCHEMBL19194217 | 0.71 | — | — | |
| SCHEMBL761435 | 0.71 | LMNA (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2328880-B1 | 6-SUBSTITUTED BENZOXAZINES AS 5-HT-5A RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-10-31 | — | — | EP | disclosed |
| US-8183380-B2 | 2-aminoquinolines | HOFFMANN-LA ROCHE INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8163740-B2 | 6-substituted benzoxazines | HOFFMANN-LA ROCHE INC. (US) | 2012-04-24 | — | — | US | disclosed |
| EP-2328880-A2 | 6-SUBSTITUTED BENZOXAZINES AS 5-HT-5A RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2011-06-08 | — | — | EP | disclosed |
| EP-2262789-A1 | 2-AMINOQUINOLINES | F. Hoffmann-La Roche AG (CH) | 2010-12-22 | — | — | EP | disclosed |
| WO-2010026110-A2 | 6-SUBSTITUTED BENZOXAZINES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-03-11 | — | — | WO | disclosed |
| US-20100063037-A1 | 6-SUBSTITUTED BENZOXAZINES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-03-11 | — | — | US | disclosed |
| WO-2009109477-A1 | 2-AMINOQUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-11 | — | — | WO | disclosed |
| US-20090227570-A1 | 2-AMINOQUINOLINES | HOFFMANN-LA ROCHE, INC. | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227570-A1 | 2-AMINOQUINOLINES | HTR5A, HTR2C, HTR2A | CHRNA7 72/4885 |
| US-20100063037-A1 | 6-SUBSTITUTED BENZOXAZINES | HTR5A, NPY5R, GABRA5 | CHRNA7 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.